

# REGULATORY CONSIDERATIONS

EVAN B. SIEGEL<sup>1</sup> AND DUANE B. LAKINGS<sup>2</sup>

<sup>1</sup>*Ground Zero Pharmaceuticals, Inc., Irvine, California*

<sup>2</sup>*Drug Safety Evaluation Consulting, Inc., Elgin, Texas*

## Contents

- 1 The Strategic Preclinical Plan: An Integral Element in the FDA Pre-IND Consultation Process
- 2 Pharmacology
  - 2.1 Primary and Secondary Pharmacodynamics
  - 2.2 Safety Pharmacology
- 3 Pharmacokinetics
  - 3.1 Methods of Analysis: Bioanalytical Chemistry Method Development and Validation
  - 3.2 ADME
  - 3.3 Pharmacokinetic Drug–Drug and Drug–Food Interactions
- 4 Toxicology
  - 4.1 Single-Dose Toxicology
  - 4.2 Repeat-Dose Toxicology
  - 4.3 Genotoxicity
  - 4.4 Carcinogenicity
  - 4.5 Reproductive and Development Toxicity
  - 4.6 Local Tolerability
  - 4.7 Immunogenicity
  - 4.8 Immunotoxicity
  - 4.9 Other Toxicology Studies
- 5 Preclinical Conclusions
- 6 Pre-IND Manufacturing Issues
- 7 Pre-IND Clinical Issues
- References